
Serial No. 09/687,276. Applicant(s): Prayaga et al.



BEST AVAILABLE COPY

(Black outlined amino acids indicate potential regions of conserved sequence; grayed amino acids represent amino acids conservatively substituted; and non-highlighted amino acids indicate positions in which mutations to a broad range of alternative amino acid residues occurs. Sequences may be referenced by the SWISSPROT or TREMBL ID.)



On page 10, please replace Table 4 with the following Table 4:

Table 4.

PFAM alignment of a NOV1 polypeptide to the consensus sequence of the thymosin beta family

Sbjct: 1 ADKPDMGEIASFDKAKLKKTETQEKNTLPTKETIEQEK 38 (SEQ ID NO:51)

Beginning on page 13, kindly replace Table 6 with the following Table 6:

Table 6.

Comparison between a NOV2 polypeptide and mouse ephrin type-A receptor 8 precursor



Serial No. 09/687,276. Applicant(s): Prayaga et al.

Length = 1004

Score = 3036 bits (7128), Expect = 0.0 Identities = 945/992 (95%), Positives = 964/992 (96%), Gaps = 1/992 (0%) MAPARGRLPPALWVVTAAAAAATCVSAARGEVNLLDTSTIHGDWGWLTYPAHGWDSINEV 60 NOV2: MAPARARLSPALWVVTAAAAA-TCVSAGRGEVNLLDTSTIHGDWGWLTYPAHGWDSINEV 59 Sbjct: 1 DESFQPIHTYQVCNVMSPNQNNWLRTSWVPRDGARRVYAEIKFTLRDCNSMPGVLGTCKE 120 NOV2: 61 Sbjct: 60 DESFRPIHTYQVCNVMSPNQNNWLRTNWVPRDGARRVYAEIKFTLRDCNSIPGVLGTCKE 119 121 TFNLYYLESDRDLGASTQESQFLKIDTIAADESFTGADLGVRRLKLNTEVRSVGPLSKRG 180 NOV2: Sbjct: 120 TFNLHYLESDRDLGASTQESQFLKIDTIAADESFTGADLGVRRLKLNTEVRGVGPLSKRG 179 181 FYLAFQDIGACLAILSLRIYYKKCPAMVRNLAAFSEAVTGADSSSLVEVRGQCVRHSEER 240 NOV2: Sbjct: 180 FYLAFQDIGACLAILSLRIYYKKCPAMVRNLAAFSEAVTGADSSSLVEVRGQCVRHSEER 239 241 DTPKMYCSAEGEWLVPIGKCVCSAGYEERRDACVACELGFYKSAPGDQLCARCPPHSHSA 300 NOV2: Sbjct: 240 DTPKMYCSAEGEWLVPIGKCVCSAGYEERRDACMACELGFYKSAPGDQLCARCPPHSHSA 299 301 APAAQACHCDLSYYRAALDPPSSACTRPPSAPVNLISSVNGTSVTLEWAPPLDPGGRSDI 360 NOV2: Sbjct: 300 TPAAQTCRCDLSYYRAALDPPSAACTRPPSAPVNLISSVNGTSVTLEWAPPLDPGGRSDI 359 361 TYNAVCRRCPWALSRCEACGSGTRFVPQQTSLVQASLLVANLLAHMNYSFWIEAVNGVSD 420 NOV2: Sbjct: 360 TYNAVCRRCPWALSHCEACGSGTRFVPQQTSLAQASLLVANLLAHMNYSFWIEAVNGVSN 419 NOV2: 421 LSPEPRRAAVVNITTNQAAPSQVVVIRQERAGQTSVSLLWQEPEQPNGIILEYEIKYYEK 480 Sbjct: 420 LSPEPRSAAVVNITTNQAAPSQVVVIRQERAGQTSVSLLWQEPEQPNGIILEYEIKYYEK 479 NOV2: 481 DKEMOSYSTLKAVTTRATVSGLKPGTRYVFQVRARTSAGCGRFSQAMEVETGKPRPRYDT 540 Sbjct: 480 DKEMQSYSTLKAVTTRATVSGLKPGTRYVFQVRARTSAGCGRFSQAMEVETGKPRPRYDT 539 541 RTIVWICLTLITGLVVLLLLLICKKRHCGYSKAFQDSDEEKMHYQNGQAPPPVFLPLHHP 600 NOV2: Sbjct: 540 RTIVWICLTLITGLVVLLLLLICKKRHCGYSKAFQDSDEEKMHYQNGQAPPPVFLPLNHP 599 601 PGKLPEPQFYAEPHTYEEPGRAGRSFTREIEASRIHIEKIIGSGDSGEVCYGRLRVPGQR 660 NOV2: Sbjct: 600 PGKFPETQFSAEPHTYEEPGRAGRSFTREIEASRIHIEKIIGSGESGEVCYGRLQVPGQR 659 NOV2: 661 DVPVAIKALKAGYTERQRRDFLSEASIMGQFDHPNIIRLEGVVTRGRLAMIVTEYMENGS 720 Sbjct: 660 DVPVAIKALKAGYTERQRQDFLSEAAIMGQFDHPNIIRLEGVVTRGRLAMIVTEYMENGS 719 721 LDTFLRTHDGQFTIMQLVGMLRGVGAGMRYLSDLGYVHRDLAARNVLVDSNLVCKVSDFG 780 NOV2: 1111111 Sbjct: 720 LDAFLRTHDGQFTIVQLVGMLRGVGAGMRYLSDLGYIHRDLAARNVLVDGRLVCKVSDFG 779 781 LSRVLEDDPDAAYTTTGGKIPIRWTAPEAIAFRTFSSASDVWSFGVVMWEVLAYGERPYW 840 NOV2: Sbjct: 780 LSRALEDDPEAAYTTAGGKIPIRWTAPEAIAFRTFSSASDVWSFGVVMWEVLAYGERPYW 839 841 NMTNRDVISSVEEGYRLPAPMGCPHALHQLMLDCWHKDRAQRPRFSQIVSVLDALIRSPE 900 NOV2: Sbjct: 840 NMTNQDVISSVEEGYRLPAPMGCPRALHQLMLDCWHKDRAQRPRFAHVVSVLDALVHSPE 899 NOV2: 901 SLRATATVSRCPPPAFVRSCFDLRGGSGGGGGLTVGDWLDSIRMGRYRDHFAAGGYSSLG 960

```
Serial No. 09/687,276.
Applicant(s): Prayaga et al.
```

Sbjct: 900 SLRATATVSRCPPPAFARSCFDLRAGGSGNGDLTVGDWLDSIRMGRYRDHFAAGGYSSLG 959

NOV2: 961 MVLRMNAQDVRALGITLMGHQKKILGSIQTMR 992 (SEQ ID NO:5)

Sbjct: 960 MVLRMNAQDVRALGITLMGHQKKILGSIQTMR 991 (SEQ ID NO:52)

Beginning on page 14, please replace Table 6A with the following Table 6A:

Table 6A. Comparison between a NOV2 polypeptide and human ephrin receptor EphA8

```
>ref|NP_065387.1| EphA8; Ephrin receptor EphA8 (eph- and elk-related kinase); Hek3;
       eph-, elk-related tyrosine kinase; ephrin receptor EphA8
emb | CAB81612.1 | (AL035703) dJ61A9.1 (tyrosine kinase ) [Homo sapiens]
       Length = 1005
Score = 2054 bits (5262), Expect = 0.0
Identities = 992/992 (100%), Positives = 992/992 (100%)
       MAPARGRLPPALWVVTAAAAAATCVSAARGEVNLLDTSTIHGDWGWLTYPAHGWDSINEV 60
NOV2 : 1
        Sbjct: 1
       MAPARGRLPPALWVVTAAAAAATCVSAARGEVNLLDTSTIHGDWGWLTYPAHGWDSINEV 60
       DESFQPIHTYQVCNVMSPNQNNWLRTSWVPRDGARRVYAEIKFTLRDCNSMPGVLGTCKE 120
NOV2 : 61
        DESFOPIHTYOVCNVMSPNONNWLRTSWVPRDGARRVYAEIKFTLRDCNSMPGVLGTCKE 120
Sbict: 61
NOV2 : 121 TFNLYYLESDRDLGASTQESQFLKIDTIAADESFTGADLGVRRLKLNTEVRSVGPLSKRG 180
NOV2 : 181 FYLAFQDIGACLAILSLRIYYKKCPAMVRNLAAFSEAVTGADSSSLVEVRGQCVRHSEER 240
        Sbjct: 181 FYLAFQDÍGACLAILSLRÍYYKKCPAMVRNLAAFSEAVTGADSSSLVEVRGQCVRHSEER 240
NOV2 : 241 DTPKMYCSAEGEWLVPIGKCVCSAGYEERRDACVACELGFYKSAPGDQLCARCPPHSHSA 300
NOV2 : 301 APAAQACHCDLSYYRAALDPPSSACTRPPSAPVNLISSVNGTSVTLEWAPPLDPGGRSDI 360
        Sbjct: 301 APAAQACHCDLSYYRAALDPPSSACTRPPSAPVNLISSVNGTSVTLEWAPPLDPGGRSDI 360
NOV2: 361 TYNAVCRRCPWALSRCEACGSGTRFVPQQTSLVQASLLVANLLAHMNYSFWIEAVNGVSD 420
        Sbjct: 361 TYNAVCRRCPWALSRCEACGSGTRFVPQQTSLVQASLLVANLLAHMNYSFWIEAVNGVSD 420
NOV2: 421 LSPEPRRAAVVNITTNQAAPSQVVVIRQERAGQTSVSLLWQEPEQPNGIILEYEIKYYEK 480
        Sbjct: 421 LSPEPRRAAVVNITTNQAAPSQVVVIRQERAGQTSVSLLWQEPEQPNGIILEYEIKYYEK 480
NOV2: 481 DKEMQSYSTLKAVTTRATVSGLKPGTRYVFQVRARTSAGCGRFSQAMEVETGKPRPRYDT 540
NOV2 : 541 RTIVWICLTLITGLVVLLLLLICKKRHCGYSKAFQDSDEEKMHYQNGQAPPPVFLPLHHP 600
        Sbjct: 541 ŘŤÍVWIČLŤLÍŤĠĽVVĽĽĽĽĽČKKŘHČGÝŠKÁFQDSDEEKMHÝQNGQÁPPPVFLPĽHHP 600
NOV2 : 601 PGKLPEPQFYAEPHTYEEPGRAGRSFTREIEASRIHIEKIIGSGDSGEVCYGRLRVPGQR 660
        Sbjct: 601 PGKLPEPOFYAEPHTYEEPGRAGRSFTREIEASRIHIEKIIGSGDSGEVCYGRLRVPGOR 660
```



Serial No. 09/687,276, Applicant(s): Prayaga et al. NOV2 : 661 DVPVAIKALKAGYTERQRRDFLSEASIMGQFDHPNIIRLEGVVTRGRLAMIVTEYMENGS 720 Sbjct: 661 DVPVAIKALKAGYTERQRRDFLSEASIMGQFDHPNIIRLEGVVTRGRLAMIVTEYMENGS 720 NOV2 : 721 LDTFLRTHDGQFTIMQLVGMLRGVGAGMRYLSDLGYVHRDLAARNVLVDSNLVCKVSDFG 780 Sbjct: 721 LDTFLRTHDGGFTIMQLVGMLRGVGAGMRYLSDLGYVHRDLAARNVLVDSNLVCKVSDFG 780 NOV2 : 781 LSRVLEDDPDAAYTTTGGKIPIRWTAPEAIAFRTFSSASDVWSFGVVMWEVLAYGERPYW 840 NOV2 : 841 NMTNRDVISSVEEGYRLPAPMGCPHALHQLMLDCWHKDRAQRPRFSQIVSVLDALIRSPE 900 Sbjct: 841 NMTNRDVISSVEEGYRLPAPMGCPHALHQLMLDCWHKDRAQRPRFSQIVSVLDALIRSPE 900 NOV2: 901 SLRATATVSRCPPPAFVRSCFDLRGGSGGGGGLTVGDWLDSIRMGRYRDHFAAGGYSSLG 960 Sbjct: 901 SLRATATVSRCPPPAFVRSCFDLRGGSGGGGLTVGDWLDSIRMGRYRDHFAAGGYSSLG 960 NOV2 : 961 MVLRMNAQDVRALGITLMGHQKKILGSIQTMR 992 (SEQ ID NO:5)

On page 16, kindly replace the paragraph in Table 7 beginning at line 4 with the following:

Sbjct: 961 MVLRMNAODVRALGITLMGHOKKILGSIOTMR 992 (SEQ ID NO:53)

Table 7 shows multiple sequence alignment of the NOV2 ephrim type-A receptor 8-like protein of the invention, shown as AL035703 Spliced2, with similar proteins. The various aligned proteins are as follows: AL035703 Spliced2 (SEQ ID NO:5) with several proteins: EPA8 Mouse (SEQ ID NO:54), EPA5 Human (SEQ ID NO:55) and EPA5 Chick (SEQ ID NO:56). (Black outlined amino acids indicate potential regions of conserved sequence; greyed amino acids represent amino acids conservatively substituted; and non-highlighted amino acids indicate positions in which mutations to a broad range of alternative amino acid residues occurs)

On page 20, please replace the paragraph in Table 9 beginning at line 5 with the following:

Table 9 shows sequence alignment between a NOV3 polypeptide with several members of the human fibronectin leucine repeat transmembrane family: AAF28461.1|AF169 (SEQ ID NO:57), AAF28460.1|AF169 (SEQ ID NO:58) and AAF28459.1|AF169 (SEQ ID NO:59). (Black outlined amino acids indicate potential regions of conserved sequence; greyed amino acids represent amino acids conservatively substituted; and non-highlighted amino acids indicate positions in which mutations to a broad range of alternative amino acid residues occurs)

On page 21, kindly replace Table 9. continued with the following Table 9A:

TABLE 9A.

```
NOV3: 1
       MVVAHPTATATTTPTATVTATVVMTTATMDLRDWLFLCYGLIAFLTEVIDSTTCPSVCRC 60
        MVVÁHPTÁTATTPTÁTVTÁTVVMTTATMÓLRÓWLFLCYGLÍÁFLTEVIÓSTTCPSVCRC 60
Sbjct: 1
       DNGFIYCNDRGLTSIPADIPDDATTLYLQNNQINNAGIPQDLKTKVNVQVIYLYENDLDE 120
NOV3:
        Sbjct: 61
       DNGFIYCNDRGLTSIPADIPDDATTLYLQNNQINNAGIPQDLKTKVNVQVIYLYENDLDE 120
    121 FPINLPRSLRELHLQDNNVRTIARDSLARIPLLEKLHLDDNSVSTVSIEEDAFADSKQLK 180
        Sbjct: 121 FPINLPRSLRELHLQDNNVRTIARDSLARIPLLEKLHLDDNSVSTVSIEEDAFADSKOLK 180
NOV3: 181 LLFLSRNHLSSIPSGLPHTLEELRLDDNRISTIPLHAFKGLNSLRRLVLDGNLLANORIA 240
        Sbjct: 181 LLFLSRNHLSSIPSGLPHTLEELRLDDNRISTIPLHAFKGLNSLRRLVLDGNLLANQRIA 240
    241 DDTFSRLQNLTELSLVRNSLAAPPLNLPSAHLQKLYLQDNAISHIPYNTLAKMRELERLD 300
NOV3:
        Sbjct: 241 DDTFSRLONLTELSLVRNSLAAPPLNLPSAHLOKLYLODNAISHIPYNTLAKMRELERLD 300
     301 LSNNNLTTLPRGLFDDLGNLAOLLLRNNPWFCGCNLMWLRDWVKARAAVVNVRGLMCOGP 360
        Sbjct: 301 LSNNNLTTLPRGLFDDLGNLAQLLLRNNPWFCGCNLMWLRDWVKARAAVVNVRGLMCQGP 360
    361 EKVRGMAIKDITSEMDECFETGPQGGVANAAAKTTASNHASATTPQGSLFTLKAKRPGLR 420
        Sbjct: 361 EKVRGMAIKDITSEMDECFETGPOGGVANAAAKTTASNHASATTPOGSLFTLKAKRPGLR 420
    421 LPDSNIDYPMATGDGAKTLAIHVKALTADSIRITWKATLPASSFRLSWLRLGHSPAVGSI 480
        Sbjct: 421 LPDSNIDYPMATGDGAKTLAIHVKALTADSIRITWKATLPASSFRLSWLRLGHSPAVGSI 480
    481 TETLVQGDKTEYLLTALEPKSTYIICMVTMETSNAYVADETPVCAKAETADSYGPTTTLN 540
NOV3:
        Sbjct: 481 TETLVQGDKTEYLLTALEPKSTYIICMVTMETSNAYVADETPVCAKAETADSYGPTTTLN 540
     541 QEQNAGPMASLPLAGIIGGAVALVFLFLVLGAICWYVHQAGELLTRERAYNRGSRKKDDY 600
        Sbjct: 541 QEQNAGPMASLPLAGIIGGAVALVFLFLVLGAICWYVHQAGELLTRERAYNRGSREKDDY 600
     601 MESGTKKDNSILEIRGPGLQMLPINPYRAKEEYVVHTIFPSNGSSLCKATHTIGYGTTRG 660
NOV3:
        Sbjct: 601 MESGTKKDNSILEIRGPGLQMLPINPYRAKEEYVVHTIFPSNGSSLCKATHTIGYGTTRG 660
     661 YRDGGIPDIDYSYT 674 (SEQ ID NO:7)
NOV3:
        Sbjct: 661 YRDGGIPDIDYSYT 674 (SEQ ID NO:60)
```



On page 22, please replace the paragraph in Table 10 beginning at line 6 with the following: